{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
glycerol phenylbutyrate
to a specific field?
1,2-DIMYRISTOYL-SN-GLYCERO-3-(PHOSPHO-S-(1-GLYCEROL)), SODIUM SALT is a prototype for the preparation of liposomes with negatively charged hydrophilic head groups. It can be used in the generation of different types of artificial membranes.
Status:
US Previously Marketed
Source:
MOCTANIN by ETHITEK
(1985)
Source URL:
First approved in 1985
Source:
MOCTANIN by ETHITEK
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Glyceryl 1-caprylate (Monooctanoin, Capmul 8210), a semisynthetic esterified glycerol, a cholesterol solvent, that has been used for the dissolution of retained cholesterol gallstones following cholecystectomy. Bile duct infusion of monooctanoin is associated with little toxicity, although potentially serious problems can result from absorption of the drug or tissue infiltration. Gastrointestinal side effects such as anorexia, nausea, vomiting, diarrhea, and abdominal pain have been reported most commonly. Complete gallstone dissolution has occurred in approximately 50-75 percent of patients receiving monooctanoin. Although mechanical stone removal is still considered to be the treatment of choice for retained gallstones, monooctanoin use appeared promising for stone dissolution in patients in whom mechanical removal has been unsuccessful or is impossible. Monoctanoin was approved by the U.S. Food and Drug Administration (FDA) on Oct 29, 1985. It was developed and marketed as Moctanin® by ETHITEK in US.
Status:
US Previously Marketed
Source:
GENAPAX by KEY PHARMS
(1977)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Gentian violet ((GV) hexamethyl pararosaniline, also known as crystal violet, methyl violet) is a triphenylmethane dye with anti-bacterial, anti-fungal, anti-helminithic, anti-trypanosomal, anti-angiogenic and anti-tumor properties. GV has a lengthy history and has been used successfully as monotherapy and an adjunct to treatment in a variety of diseases. Gentian violet interacts with negatively charged components of bacterial cells including the lipopolysaccharide (on the cell wall), the peptidoglycan and DNA. A similar cell penetration and DNA binding process is thought to take place for fungal cells as well. Because Gentian violet is a mutagen and mitotic poison, cell growth is consequently inhibited. A photodynamic action of gentian violet, apparently mediated by a free-radical mechanism, has recently been described in bacteria and in the protozoan T. cruzi. Evidence also suggests that gentian violet dissipates the bacterial (and mitochondrial) membrane potential by inducing permeability. This is followed by respiratory inhibition. This anti-mitochondrial activity might explain gentian violet's efficacy towards both bacteria and yeast with relatively mild effects on mammalian cells.
Status:
US Previously Marketed
Source:
OTOMIDE CHLOROBUTANOL by WHITE
(1961)
Source URL:
First marketed in 1911
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Chlorobutanol, or trichloro-2-methyl-2-propanol, is an analgesic and sedative hypnotic in man, and an experimental general anesthetic. It has antibacterial and antifungal properties. It is also used chemical preservative for parenteral drugs. It was found, that chlorobutanol inhibited mammalian Nav 1.2 channels at concentrations less than those used to preserve parenteral solutions. Its mechanism of inhibiting Na channels differs from that of local anesthetics in that it does not show use dependent or state dependent inhibition.
Status:
Possibly Marketed Outside US
Source:
ANDA214010
(2022)
Source URL:
First approved in 2022
Source:
ANDA214010
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
1,2-Distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol) is a phosphorylglycerol acylated with stearic acid. It is used for the preparation of liposomes for drug delivery.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2021)
Source URL:
First approved in 2021
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-rac-(1-glycerol) ammonium salt (POPG-NH4) ia a phospholipid. Can be used as an emulsifier in pharmaceutical compositions. Used for lipid modification of superhydrophobic surfaces. POPG-NH4 transforms the surface into a highly hydrophilic surface only at the positions where the solution is applied.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2021)
Source URL:
First approved in 2021
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-rac-(1-glycerol) ammonium salt (POPG-NH4) ia a phospholipid. Can be used as an emulsifier in pharmaceutical compositions. Used for lipid modification of superhydrophobic surfaces. POPG-NH4 transforms the surface into a highly hydrophilic surface only at the positions where the solution is applied.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
